Sulindac treatment preserves motor neurons and reduces microglial activation and astrocytosis in the spinal cord [127], suggesting that cPLA2 plays an important role in supplying arachidonic acid to the COX-2 driven inflammatory pathway in ALS associated with SOD1 mutations. This evidence concerns the gene PTGS2 and amyotrophic lateral sclerosis.